For decades, cancer treatment has been guided by the organ where the disease first appears. A tumour in the lung is treated as lung cancer, one in the breast as breast cancer. But a new strategy described in New Scientist turns that idea on its head, looking instead at the molecular makeup of the tumour itself.
This shift in analysis is already changing outcomes for some patients. According to the report, people with forms of cancer that were once considered a death sentence are now surviving, thanks to treatments selected by this tumour-focused approach rather than by location alone.
The article frames the method as revolutionary, suggesting it could beat even the worst cancers. While the piece does not provide detailed clinical data, it points to a broader trend in oncology: moving away from body-part labels and toward the biology of the tumour as the key to choosing therapy.